Cardio Diagnostics (CDIO) Competitors $0.50 +0.03 (+7.11%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.52 +0.01 (+2.08%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CDIO vs. ARTV, PROC, RANI, ATOS, CRBP, CLYM, ZURA, ANIX, CRDL, and XBITShould you be buying Cardio Diagnostics stock or one of its competitors? The main competitors of Cardio Diagnostics include Artiva Biotherapeutics (ARTV), Procaps Group (PROC), Rani Therapeutics (RANI), Atossa Therapeutics (ATOS), Corbus Pharmaceuticals (CRBP), Climb Bio (CLYM), Zura Bio (ZURA), Anixa Biosciences (ANIX), Cardiol Therapeutics (CRDL), and XBiotech (XBIT). These companies are all part of the "pharmaceutical products" industry. Cardio Diagnostics vs. Artiva Biotherapeutics Procaps Group Rani Therapeutics Atossa Therapeutics Corbus Pharmaceuticals Climb Bio Zura Bio Anixa Biosciences Cardiol Therapeutics XBiotech Cardio Diagnostics (NASDAQ:CDIO) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk. Does the MarketBeat Community favor CDIO or ARTV? Artiva Biotherapeutics received 5 more outperform votes than Cardio Diagnostics when rated by MarketBeat users. Likewise, 100.00% of users gave Artiva Biotherapeutics an outperform vote while only 80.00% of users gave Cardio Diagnostics an outperform vote. CompanyUnderperformOutperformCardio DiagnosticsOutperform Votes480.00% Underperform Votes120.00% Artiva BiotherapeuticsOutperform Votes9100.00% Underperform VotesNo Votes Do analysts recommend CDIO or ARTV? Cardio Diagnostics presently has a consensus price target of $2.00, indicating a potential upside of 296.43%. Artiva Biotherapeutics has a consensus price target of $21.00, indicating a potential upside of 457.03%. Given Artiva Biotherapeutics' higher possible upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Cardio Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of CDIO or ARTV? 8.1% of Cardio Diagnostics shares are owned by institutional investors. 22.3% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media refer more to CDIO or ARTV? In the previous week, Artiva Biotherapeutics had 3 more articles in the media than Cardio Diagnostics. MarketBeat recorded 3 mentions for Artiva Biotherapeutics and 0 mentions for Cardio Diagnostics. Artiva Biotherapeutics' average media sentiment score of 0.45 beat Cardio Diagnostics' score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Cardio Diagnostics Neutral Artiva Biotherapeutics Neutral Which has preferable earnings & valuation, CDIO or ARTV? Artiva Biotherapeutics has lower revenue, but higher earnings than Cardio Diagnostics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardio Diagnostics$35.69K737.14-$8.38MN/AN/AArtiva BiotherapeuticsN/AN/AN/AN/AN/A Is CDIO or ARTV more profitable? Artiva Biotherapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -22,732.03%. Artiva Biotherapeutics' return on equity of 0.00% beat Cardio Diagnostics' return on equity.Company Net Margins Return on Equity Return on Assets Cardio Diagnostics-22,732.03% -258.85% -191.20% Artiva Biotherapeutics N/A N/A N/A SummaryArtiva Biotherapeutics beats Cardio Diagnostics on 9 of the 12 factors compared between the two stocks. Get Cardio Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDIO vs. The Competition Export to ExcelMetricCardio DiagnosticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.31M$2.30B$5.84B$9.15BDividend YieldN/A0.75%4.75%3.85%P/E RatioN/A5.0425.4719.00Price / Sales737.1462.84447.5876.30Price / CashN/A15.7538.0134.83Price / Book3.603.287.644.62Net Income-$8.38M-$65.73M$3.18B$245.85M7 Day Performance-24.62%-3.90%-1.99%-2.68%1 Month Performance-19.52%-8.97%-0.42%-2.19%1 Year Performance-71.17%-15.59%16.51%12.84% Cardio Diagnostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDIOCardio Diagnostics1.8 of 5 stars$0.50+7.1%$2.00+296.4%-68.1%$26.31M$35,688.000.001Gap UpARTVArtiva BiotherapeuticsN/A$4.44+10.7%$21.00+373.0%N/A$107.85MN/A0.0081News CoveragePROCProcaps GroupN/A$0.95-40.3%N/A-73.4%$107.18M$409.92M0.004,900News CoverageGap DownHigh Trading VolumeRANIRani Therapeutics3.6026 of 5 stars$1.85+0.5%$12.33+566.7%-49.2%$105.99MN/A-1.75110ATOSAtossa Therapeutics1.3107 of 5 stars$0.83+1.9%$7.00+743.2%-21.3%$104.44MN/A-3.778Positive NewsCRBPCorbus Pharmaceuticals4.0286 of 5 stars$8.51-10.2%$61.38+621.2%-69.9%$103.65MN/A-1.8140Analyst ForecastGap DownHigh Trading VolumeCLYMClimb Bio2.4945 of 5 stars$1.52-4.4%$10.00+557.9%N/A$102.17MN/A-0.719ZURAZura Bio2.8396 of 5 stars$1.55+3.3%$15.80+919.4%-62.0%$101.20MN/A0.003Gap UpANIXAnixa Biosciences2.9817 of 5 stars$3.14-0.3%$8.50+170.7%-18.3%$101.11M$210,000.00-8.055Analyst ForecastAnalyst RevisionNews CoverageCRDLCardiol Therapeutics2.8824 of 5 stars$1.22-1.6%$8.40+588.5%-18.4%$100.78MN/A-3.1320News CoverageXBITXBiotech0.5091 of 5 stars$3.27+1.9%N/A-56.7%$99.67M$4.01M-3.03100 Related Companies and Tools Related Companies ARTV Competitors PROC Competitors RANI Competitors ATOS Competitors CRBP Competitors CLYM Competitors ZURA Competitors ANIX Competitors CRDL Competitors XBIT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CDIO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardio Diagnostics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardio Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
